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Abstract
Background: The purpose of the present study is to investigate the direct biological effects of the epidermal
growth factor receptor (EGFR) inhibitor C225 on the radiosensitivity of human lung squamous cancer cell-H520.
H520 cells were treated with different dosage of 60Co g ray irradiation (1.953 Gy/min) in the presence or absence
of C225. The cellular proliferation, colony forming capacity, apoptosis, the cell cycle distribution as well as caspase-3
were analyzed in vitro.
Results: We found that C225 treatment significantly increased radiosensitivity of H-520 cells to irradiation, and led
to cell cycle arrest in G1 phase, whereas
60Co g ray irradiation mainly caused G2 phase arrest. H-520 cells thus
displayed both the G1 and G2 phase arrest upon treatment with C225 in combination with
60Co g ray irradiation.
Moreover, C225 treatment significantly increased the apoptosis percentage of H-520 cells (13.91% ± 1.88%)
compared with the control group (5.75% ± 0.64%, P < 0.05).
Conclusion: In this regard, C225 treatment may make H-520 cells more sensitive to irradiation through the
enhancement of caspase-3 mediated tumor cell apoptosis and cell cycle arrest.
Introduction
It is well known that many non-small cell lung cancer
(NSCLC) cells over-express membrane surface epidermal
growth factor receptor (EGFR) [1-7]. EGFR activation led
to cell proliferation, angiogenesis and apoptosis inhibi-
tory cytokines related phosphorylation and activation of
cell signal pathway[8,9]. EGFR monoclonal antibody
cetuximab (C225, Erbitux, Merck KGaA, Germany) inhi-
bits tumor growth by directly impeding the EGFR ligands
EGF and transforming growth factor-a (TGF-a) combi-
nation of the above-mentioned cell block access [9-16].
In the in vitro studies, C225 combined with radiotherapy
or chemotherapy inhibits the growth of head and neck
squamous carcinoma cells dramatically. Furthermore, in
the clinical treatment of head and neck squamous cell
carcinoma [17,18], C225 combined with radiotherapy has
also made a fantastic therapeutic effect [14,15]. At pre-
sent, the clinical trials of C225 combined with radiother-
apy and radiotherapy alone for patients with advanced
NSCLC are under way[18], no clear conclusion has been
drawn. In this experiment H-520 cell proliferation, apop-
tosis and cell cycle distribution were detected after treat-
ing with C225 combined with radiotherapy.
Materials and methods
Cell lines and culture
The human non-small cell lung cancer cell line H-520
was purchased from Institute of Basic Medical Science,
Peking Union Medical College (Beijing, China). H-520
cells were maintained in DMEM medium which was
composed of 10% fetal calf serum, 1% penicillin and
streptomycin (penicillin 100 U/ml, streptomycin 100
mg/ml), and 1% glutamine. Cells were cultured in 37°C
incubator with 5% CO2.
Determination of EGFR expression in H-520 cells by flow
cytometry
Exponentially growing H-520 cells were adjusted to 5 ×
106/ml and incubated with mouse-against human EGFR
antibody for 30 min at 4°C. After washing with PBS
twice, the cells were treated with FITC labeled goat-
anti-mouse IgG for 30 min. The EGFR expression was
detected by flow cytometry.
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Cell treatment with C225 and irradiation
H520 cells were pre-cultured with 40 nM C225 for 12 h,
these cells and control cells then received a single dose
of g ray irradiation from a 60Co source (Peking Univer-
sity Health Science Center, China). The irradiation rate
is 1.953 Gy/min.
Cell growth analysis by methyl thiazolyl tetrazolium
(MTT) assay
Cell proliferation was determined by assessing the mito-
chondrial reduction of MTT. Cells were plated at 1 × 103
cells/well in 96-well plates containing 200 μl growth
medium and allowed to attach for 24 h. The medium was
removed. Blank control and C225 (0.008, 0.04, 0.2, 1, 5,
25, 125 and 625 nM) groups were prepared and cells
were incubated for 0, 12, 24, 48, 72 and 120 h. At harvest,
the medium was removed from the appropriate wells,
replaced with 50 μl MTT solution (2.5 mg/ml), and incu-
bated for 4 h at 37°C. After incubation, the MTT solution
was carefully aspirated and replaced with 150 ul DMSO.
Cell growth was analyzed on a plate reader by using Soft-
Max program (Molecular Devices Corp., Menlo Park,
CA). Experiments were performed in quadruplicate and
repeated at least 3 times. Inhibition ratio (%) = (1-A190
of testing group/A190 of the control group) × 100%.
Colony formation
The cells in exponential growth were digested with trypsin
into single cell suspension. Cells were seeded into 100 mm
culture plates at various dilutions. Cells were distributed
evenly in 10 ml medium and maintained in incubator at
37°C for 14 days. Then the cells were fixed with methanol
and stained with Gimsa. The colonies with more than
50 cells were counted. The plating efficiency (PE) was cal-
culated as the formula: PE = number of colonies/number
of seeded cells × 100%. Results were shown as the mean
value of quadruplicate samples in each dose.
Dose-survival curve and sensitization enhancement ratio
(SER)
The H-520 cells were exposed to 60Co g ray irradiation,
with the total dose of 100, 200, 400, 600, 800 and 1000
cGy. There are three samples in each dose group. After
irradiation, cells were digested and seeded into 100 mm
plates at different cell numbers. Then the cells were cul-
tured in 35 mm plates for 14 days, and the formed colo-
nies were counted. The survival fraction (SF) was
calculated as the formula: SF = number of colonies/
number of seeded cells × PE. The dose-survival curve
was fitted based on the one-hit multi-target formula
SF e D D N= − − −1 1 0( )/ , with cell survival percentage as
Y-axis and absorbed dose as X-axis, in which D was the
absorbed dose, D0 was the mean lethal dose, and N was
the extrapolation number. In addition, the N, D0, Dq
(quasi-threshold dose) and SERwere calculated based on
the dose-survival curve of H-520 cells irradiated with
60Co g ray, SER is defined as following: SER = (D10 of
the group irradiated with 60Co g ray)/(D10 of the group
treated with combination of 60Co and C225).
Cell apoptosis determined by Hoechst33258-staining
H-520 cells were separated into three groups: control,
C225-treated group and 8 Gy 60Co g ray irradiated group.
After incubation for 72 h, the cells were fixed and stained
with 100 μg/ml Hoechst 33258 (Beijing Lanbosite Biotech.
Co. Beijing, China) for 30 min. Cells morphology were
detected under fluorescence microscopy.
Cell cycle and apoptosis analysis by flow cytometry (FCM)
Cells from the control and C225 groups were exposed
to different dose of irradiation (0, 2, 4 and 8 Gy). Cells
were harvested at 72 h after irradiation for cell apoptosis
analyses by FCM. Cells for cycle analysis (0 and 8 Gy)
were harvested at 48 h after irradiation. Each test was
performed 3 times. Cells used for cell-cycle tests were
stained with propidium iodide. Cells used for apoptosis
tests were stained with propidium iodide (PI) and
annexin V-FITC and analyzed by fluorescence-activated
cell sorting (FACS) using Coulter EPICS and ModFit
software (Verity Software House, Topsham, MN).
The expression levels of Caspase-3 after treatment with
C225 or/and irradiation
Four groups were involved in this study: control group,
C225 group (final concentration of 40 nM), irradiation
group (8 Gy) and combination group (C225 of 40 nM
combined with irradiation of 8 Gy). Cells were collected
as before and 0.5 μL Caspase-3 specific antibody were
added to each tube, and incubated for 15 min away
from light after mixing the cell suspension. Cell suspen-
sion were adjusted to 300 μl with PBS, and analyzed
with FACS.
Statistical analysis
GraphPad prism software 4.0 was adopted to produce
dose-survival curve. The statistics was performed with
SPSS11.5 version. Measurement data were presented as
mean ± standard deviation (x ± SD). The difference
between the means of two different groups was analyzed
with t-test, while ANOVA was sued for comparing 4
groups of treatment. p < 0.05 was considered significant.
Results
High expression of EGFR in H-520 cells
In order to determine the expression of EGFR in our
cell line H520, we firstly performed indirect staining to
detect EGFR expression with FACS. The percentage of
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EGFR expression in normal lung tissue cells is below
10%. However, as shown in Figure 1, 82% of the H-520
cells expressed EGFR.
Effects of C225 on H-520 cell growth
From our previous study, we found the 40 nM C225
treatment showed approximately 50% inhibition of H-
520 cell growth. We thus used 40 nM C225 for further
analysis. We incubated H-520 cells with 40 nM C225
for different time points, and found that the growth
inhibition rate was about 50% 72 hours after 40 nM
C225 treatment. Prolonged treatment did not lead to
higher growth inhibition, as shown in Figure 2.
Enhanced radiosensitivity in EGFR inhibitor C225-treated
H-520 cells
The radiobiological parameters of C225-treated H-520
cells were D0 = 1.32 Gy, Dq = 0.19 Gy, N = 1.352,
while those of C225-untreated H-520 cells were D0 =
1.82 Gy, Dq = 0.51 Gy, N = 1.81. In the present
study, the SER was about 1.35, which indicated that
treatment with C225 significantly improved the biolo-
gical effect of irradiation. The results were shown in
Figure 3.
Figure 1 H-520 cells express high levels of EGFR . The
percentage of EGFR expressing cells in H-520 cells was determined
by FACS. The upper panel (A) shows isotype control, which stains
only with secondary antibody. The lower panel (B) shows that 82%
of the H-520 cells expressed EGFR as stained positively for EGFR
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Figure 2 Growth inhibitory effects of C225 on human non-
small cell lung cancer cells. Using MTT assay, we incubated H-520
cells with 40 nM C225 for different time points, and found that the
growth inhibition rate was about 50% 72 hours after 40 nM C225
treatment. Further treatment did not cause higher growth
inhibition. One representative of two experiments was shown.










Figure 3 Radiosensitivity was enhanced by EGFR inhibitor
C225. SER calculation was carried out and we found that treatment
with C225 significantly improved the biological effect of irradiation.
The radiobiological parameters of C225-treated H-520 cells were D0
= 1.32, Dq = 0.19, N = 1.352, while those of irradiated H-520 cells
were D0 = 1.82, Dq = 0.51, N = 1.81. Data were shown as Mean +
SD (N = 4). One representative of three experiments with identical
results was shown.
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Significantly enhanced cell apoptosis in C225-treated H-
520 cells after irradiation
Under fluorescent microscope, it appeared apparently
that, compared with irradiation group, C225 treatment
together with irradiation significantly induced morpho-
logical changes of H-520 cells, including the majority of
cells’ nuclei was wavy (rippled), cell membrane folded,
chromatin condensed, some of which were cracking as
the fragments of the nucleus, resulting in the appear-
ance of apoptotic bodies (data not shown).
The percentage of apoptosis cells was determined by
flow cytometry. The apoptosis rate of H-520 cells under
conventional culture conditions was about 5%, however
C225 rose the percentage of cell apoptosis to 13.91 ±
1.88 (t = 3.59, P < 0.05, Figure 4). The apoptosis percen-
tage of control group irradiated with 2, 4, or 8 Gy g ray
respectively was 13.88 ± 2.38, 24.67 ± 1.77, 30.36 ± 2.81,
after treated with C225 coupled with irradiation the
apoptosis percentage was 23.33 ± 3.18 (t = 2.16, P <
0.05), 39.01 ± 0.173 (t = 4.74, P < 0.05), and 42.46 ±
4.06 (t = 5.65, P < 0.05), respectively. There was
significant difference between C225 and irradiation
combination group and irradiation group. The results
were summarized in Table 1.
C225 arrested the cell cycle of H-520 cells at G0/G1 phase
As shown in Figure 5, C225 arrested the cell cycle of H-
520 at G0/G1 phase from 43.64 ± 1.54% to 52.55 ±
2.67% determined by flow cytometry. Meanwhile, g ray
irradiation arrested the cell cycle at G2/M phase from
10.83 ± 1.52% to 29.95 ± 2.6%; when C225 coupled with
irradiation the cell cycle arrested at both G0/G1 and G2/
M phase, meanwhile the proportion of S phase reduced
from 45.46 ± 0.06% to 21.12 ± 6.84%.
C225 increased the ratio of caspase-3 in H520 cells
The percentage of caspase-3-positive cells in control
group, C225 group, irradiated group and C225 coupled
with irradiation group was 7.8 ± 0.94, 54.1 ± 7.56, 17.7
± 2.1, and 66.9 ± 10.4, respectively. C225 increased the
ratio of caspase-3 positive cells significantly (p < 0.05).
The results were shown in Figure 6.





Figure 4 Apoptosis of H520 cells induced by irradiation and C225. H520 cells were treated with C225 or/and different doses of irradiation.
The apoptosis was determined by flow cytometry. The results were summarized in Table 1. One representative of three experiments with
identical results was shown.
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Discussion
The incidence and mortality of lung cancer are high and
Lung cancer is the leading cause of cancer-related deaths
[19]. Clinical diagnosis of 80-87% of patients with lung
cancer is non-small cell lung cancer. Currently, radio-
therapy and chemotherapy combined treatment for
locally advanced NSCLC is the standard treatment pro-
gram. One of the characteristics of chemotherapy is
based on two kinds of platinum-based drugs in combina-
tion with radiation therapy to sequential or simultaneous
delivery methods [20]. Though the new chemotherapy
drugs and new drug combination has been introduced
into the program, conventional radiotherapy has been
substituted by three-dimensional stereotactic radiother-
apy. Statistics show that over the past two decades, the
survival time of patients with NSCLC remains no change.
We found that the clinical treatment of the same stages
and even the same type of patients using the same treat-
ment, the patient’s prognosis are different, it prompt us
to speculate that the tumor pathological type may have a
great impact on therapy options and prognosis of
patients. In recent years, bio-molecular targeting therapy
increasingly receives attention. In non-Hodgkin’s lym-
phoma, renal cell cancer, colorectal cancer, non-small
cell lung cancer and head and neck squamous cells can-
cer treatment, bio-targeting drugs have made a good
effect [18,21].
Clinically, anti-EGFR monoclonal antibody C225 com-
bined with radiotherapy showed a significant effect on
head and neck squamous cell carcinoma, the C225 com-
bined with radiotherapy as the conventional treatment
options on head and neck squamous cell carcinoma have
been acceptable to the majority of doctors [21,22]. Many
biological characteristics of advanced NSCLC are consis-
tent with the head and neck cancer. Squamous cell carci-
noma is the majority of NSCLC, so in this experiment we
use H-520 cells as research materials to observe the
effects of C225 and 60Co g treatment (alone/coupled) on
the proliferation, apoptosis and changes in the cell cycle.
In the present study, we used H-520 cells as human
non-small cell lung cancer cells. Though it is reported
that H-520 cells do not express EGFR[20,23], we detected
high level expression of EGFR as determined by flow
cytometry. The inconsistency between our results and
the published data may be due to the long term cell
culture, the selected clone expansion and the other rea-
sons in our labs, which should be determined in the
future. The expression of EGFR may make our H-520
cells more sensitive to C225 treatment so that we can
study the co-effect of radiation of C225 in this cell line.
Table 1 H-520 cells apoptosis rate
Apoptosis rate (%, × ± SD)
Groups 0Gy 2Gy 4Gy 8Gy
Control 5.75 ± 0.64 13.88 ± 2.38 24.67 ± 1.77 30.36 ± 2.81
C225 13.91 ± 1.88a 23.33 ± 3.18b 39.01 ± 0.73c 42.46 ± 4.06d
Note: T test for the apoptosis rate of two groups at the same dose,









































Figure 5 C225 arrested the cell cycle of H-520 at G0/G1 phase.
C225 treatment caused H-520 cell cycle arrested at G0/G1 phase, 52.55
± 2.67% compared with control cells 43.64 ± 1.54%. In the meantime,
g-ray irradiation arrested the cell cycle at G2/M phase from 10.83 ±
1.52% to 29.95 ± 2.6%; C225 treatment together with irradiation led to
cell cycle arrest at both G0/G1 and G2/M phase, thus the proportion of
S phase reduced from 45.46 ± 0.06% to 21.12 ± 6.84%.
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Colony forming efficiency analysis is a classical
method to evaluate the anti-tumor ability of g ray irra-
diation. Through analysis of cell survival curves we
found that the N value of C225 combined with radio-
therapy is smaller, the curves had no apparent shoulder
area, which indicate that the C225 increased the sensi-
tivity of the H-520 cells to 60Co g ray irradiation. At the
same time, the D0 Value is relatively lower suggesting
that the reasonable lower doses of 60Co g ray can also
kill tumor cells when coupled with C225. The SER of
C225 treatment is about 1.4 which suggested that C225
had radiosensitization effect on the H-520 cells. It has
been studied that after irradiation the expression of
EGFR and TGF-a increased which enhanced the ability
of the tumor cells to repair DNA damage, and rapidly
proliferate [24,25]. The C225 which can combine with
EGFR not only blocked the secretion of TGF-a and sig-
nal transduction but also decreased the expression of
EGFR on the cell membrane surface [16]. These
impeded the cell survival and proliferation.
The cell-cycle phase is one of the determinative fac-
tors of cell radiosensitivity [26]. In the present study we
observed C225 arrested the cell cycle at the G0/G1
phase, 60Co g ray irradiation resulted in G2/M phase
arrest, C225 in combination with 60Co g ray irradiation
at the same time led to the cell cycle arrested at G0/G1,
G2/M phase. Under normal condition, cell cycle arrests
at some point in order to repair damage, when the
damage repairs successfully, cell cycle continues, other-
wise cells undergo apoptosis. It needs the participation
of many growth factors to repair the irradiation induced
damage for the cells arrested at G2/M phase [27]. When
the EGFR pathway is blocked by C225, the repair is dif-
ficult to proceed smoothly, the cells will undergo apop-
tosis. With this match, C225 in combination with
irradiation significantly increased the rate of apoptosis.
Caspase-3 plays an important role in the apoptosis pro-
cess which hydrolytic DNA led cells to apoptosis, cas-
pase-3 positive cells will be apoptotic eventually [28]. We
found that C225 increased the number of caspase-3-posi-
tive cells significantly, the mechanism may be that C225
against with EGFR blocked the PI3K pathway which
reduced Akt phosphorylation (Akt is an important pro-
tein molecule in PI3K pathway, it regulates caspase-9,
GSK-3b, NF-B, such as protein phosphorylation and
ultimately controls cell survival and apoptosis) and then
activated caspase-9 and process of apoptosis using cas-
pase-3 to cut DNA to complete the task of apoptosis.
In summary, C225, which blocks EGFR pathway,
inhibited H520 lung squamous carcinoma cell prolifera-
tion, and increased the sensitivity of lung squamous can-
cer cells to irradiation dramatically.
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